Verona Pharma Plc
(NASDAQ : VRNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SAVACassava Sciences, Inc. -13.07%77.990.0%$199.45m
HZNPHorizon Therapeutics Plc -1.11%92.845.5%$177.22m
VRXValeant Pharmaceuticals International, Inc. -0.27%29.2614.1%$172.17m
JAZZJazz Pharmaceuticals Plc -0.65%176.072.2%$124.07m
ICLRICON plc -1.29%209.974.2%$107.51m
CTLTCatalent, Inc. -0.27%109.462.1%$99.64m
SAGESAGE Therapeutics, Inc. -3.03%55.707.6%$74.12m
UTHRUnited Therapeutics Corp. 0.47%181.0514.0%$68.52m
ARGXargenx SE -1.82%313.990.0%$65.38m
BHCBausch Health Cos., Inc. -0.27%29.260.0%$58.19m
PRGOPerrigo Co. Plc -1.55%46.466.9%$57.37m
PCRXPacira Biosciences, Inc. -1.97%59.879.9%$29.39m
AXSMAxsome Therapeutics, Inc. 0.19%70.891.9%$24.95m
IRWDIronwood Pharmaceuticals, Inc. 2.20%12.349.6%$23.36m
RVMDRevolution Medicines, Inc. -5.91%32.540.0%$23.24m

Company Profile

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.